Removing Endogenous TCR Chains for Enhanced TCR-Based Immunotherapies
Summary
USPTO published patent application US20260097079A1 by Khosravi Maharlooei et al. disclosing methods for treating diseases using adoptive cell therapy with modified lymphocytes having inactivated endogenous TCRα and TCRβ chains. The application covers compositions and methods for enhanced TCR-based immunotherapies.
What changed
The USPTO published patent application US20260097079A1 covering methods and compositions for treating diseases using adoptive cell therapy (ACT) with modified lymphocytes featuring inactivated endogenous TCRα and TCRβ chains.
Pharmaceutical and biotechnology companies developing TCR-based immunotherapies should monitor this patent, as it may affect freedom-to-operate assessments for cell therapy programs and could require licensing negotiations.
What to do next
- Monitor for updates
- Review patent claims for freedom-to-operate
- Consider licensing negotiations
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
REMOVAL OF ENDOGENOUS TCR CHAINS FOR ENHANCED TCR-BASED IMMUNOTHERAPIES
Application US20260097079A1 Kind: A1 Apr 09, 2026
Inventors
Mohsen Khosravi MAHARLOOEI, Giorgia ZANETTI, Remi CREUSOT, Megan SYKES
Abstract
Methods and compositions for treating a disease in a subject comprising administering an adoptive cell therapy (ACT) to the subject, the ACT comprising delivering a modified lymphocyte comprising a modified T cell receptor (TCR) or a chimeric antigen receptor (CAR);
at least one inactivated endogenous TCRα chain allele; and at least one inactivated endogenous TCRβ chain allele.
CPC Classifications
A61K 35/17 A61K 40/11 A61K 40/31 A61K 40/32 A61K 48/005 A61P 37/06 C07K 14/7051 C12N 9/226 C12N 15/111 C12N 15/86 C12N 2310/20 C12N 2740/15043
Filing Date
2025-12-11
Application No.
19415932
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.